As we move through 2026, three mega-trends are distinctly shaping the peptide industry. First, Artificial Intelligence (AI) is revolutionizing de novo peptide design, enabling the rapid prediction of binding affinities and pharmacokinetic properties, thereby slashing early-stage R&D timelines. Recent advances in AI have shifted the focus towards structure prediction, generative design, and interaction modelling, significantly accelerating drug design and discovery[reference:73].
AI-driven peptide design is being advanced through strategic partnerships. LG AI Research has announced a collaboration with D&D Pharmatech to accelerate next-generation oral peptide drug discovery[reference:74]. Under this partnership, LG AI Research will develop models to design and discover new peptide drug candidates[reference:75]. TandemAI and Perpetual Medicines have merged to create a unified platform for peptide drug discovery, aiming to shorten development cycles in a segment of medicine known for complexity and delay[reference:76].
Second, oral peptide delivery is achieving breakthrough milestones. Novel permeation enhancers and enteric coating technologies are allowing for subcutaneous-to-oral switching of blockbuster drugs like semaglutide. This is set to dramatically expand patient populations and market sizes. Novo's Wegovy pill for weight loss debuted in early January 2026, notching more than 18,400 prescriptions in its first week[reference:77]. Lilly's orforglipron pill for weight loss is currently under expedited FDA review[reference:78]. The global oral proteins and peptides market is projected to grow from USD 9.31 billion in 2025 to USD 19.93 billion by 2030 at a CAGR of 16.4%[reference:79].
Third, multi-target agonists (e.g., tri-agonists targeting GLP-1, GIP, and Glucagon receptors) are emerging as the new standard for complex metabolic diseases, showing superior efficacy compared to mono-agonists. These trends collectively signal a future where peptides are more accessible, more effective, and developed faster than ever before. The peptide therapeutics market is expected to grow to $83.57 billion in 2030 at a CAGR of 11.2%[reference:80].
Additional trends include the expansion of precision medicine applications using peptides, integration of cloud and big data for peptide research, use of IoT-enabled laboratory devices for real-time monitoring, and implementation of smart manufacturing in peptide production[reference:81]. The industry is also seeing a commitment to greener manufacturing, with pressure to reduce reliance on DMF and NMP in SPPS and adopt more efficient hybrid approaches[reference:82]. These trends are collectively transforming the peptide industry, making it more innovative, efficient, and accessible than ever before.